Biomarker-Based Management of AKI: Fact or Fantasy?

Marlies Ostermann; Emma Karsten; Nuttha Lumlertgul

doi:10.1159/000518365

Biomarker-Based Management of AKI: Fact or Fantasy?

Nephron. 2022;146(3):295-301. doi: 10.1159/000518365. Epub 2021 Aug 26.

Authors

Marlies Ostermann¹, Emma Karsten², Nuttha Lumlertgul^{1

3

4}

Affiliations

¹ Department of Critical Care, King's College London, Guy's & St Thomas' NHS Foundation Trust, London, UK.
² Emergency Department, Guy's & St Thomas' Foundation Trust, London, UK.
³ Division of Nephrology, Department of Internal Medicine and Excellence Center in Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
⁴ Research Unit in Critical Care Nephrology, Chulalongkorn University, Bangkok, Thailand.

Abstract

New biomarkers for acute kidney injury (AKI) have improved our understanding of the etiology and pathogenesis of AKI. Depending on their origin, function, and kinetic profile, biomarkers have a role in screening, diagnosis, prognostication, and monitoring of AKI. This offers opportunities to improve the management of AKI, but concerns and limitations remain. In this review, we summarize the current role of new AKI biomarkers in the management of AKI and outline some of the ongoing limitations and challenges.

Keywords: Acute kidney injury; Biomarkers.

Publication types

Review

MeSH terms

Acute Kidney Injury* / diagnosis
Acute Kidney Injury* / therapy
Biomarkers
Fantasy*
Female
Humans
Male

Substances

Biomarkers